Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2532-7151
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees19
Next Earnings Date4/23/2019 (Estimated)
OptionableNot Optionable
Entera Bio (NASDAQ:ENTX) Frequently Asked Questions
What is Entera Bio's stock symbol?
Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."
How were Entera Bio's earnings last quarter?
Entera Bio Ltd (NASDAQ:ENTX) released its quarterly earnings results on Tuesday, January, 22nd. The company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.17. View Entera Bio's Earnings History.
When is Entera Bio's next earnings date?
What price target have analysts set for ENTX?
1 brokers have issued twelve-month price targets for Entera Bio's stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Entera Bio's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 164.3% from the stock's current price. View Analyst Price Targets for Entera Bio.
What is the consensus analysts' recommendation for Entera Bio?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Entera Bio.
Has Entera Bio been receiving favorable news coverage?
Headlines about ENTX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Entera Bio earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Entera Bio's key competitors?
Some companies that are related to Entera Bio include La Jolla Pharmaceutical (LJPC), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Jounce Therapeutics (JNCE), Allena Pharmaceuticals (ALNA), Organovo (ONVO), Neon Therapeutics (NTGN), Surface Oncology (SURF), Pluristem Therapeutics (PSTI), Outlook Therapeutics (OTLK), Champions Oncology (CSBR), Nantkwest (NK), Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI) and INmune Bio (INMB).
What other stocks do shareholders of Entera Bio own?
Who are Entera Bio's key executives?
Entera Bio's management team includes the folowing people:
- Dr. Phillip Schwartz Ph.D., CEO & Director (Age 57)
- Dr. Hillel Galitzer, Chief Operating Officer (Age 41)
- Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 65)
- Ms. Mira Rosenzweig, Chief Financial Officer (Age 47)
- Dr. Arthur C. Santora II, Chief Medical Officer
When did Entera Bio IPO?
(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.
When did the company's lock-up period expire?
Entera Bio's lock-up period expired on Tuesday, December 25th. Entera Bio had issued 1,400,000 shares in its IPO on June 28th. The total size of the offering was $11,200,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
Who are Entera Bio's major shareholders?
Entera Bio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Worth Venture Partners LLC (0.24%) and FNY Investment Advisers LLC (0.13%).
Which institutional investors are buying Entera Bio stock?
ENTX stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and Worth Venture Partners LLC.
How do I buy shares of Entera Bio?
Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Entera Bio's stock price today?
One share of ENTX stock can currently be purchased for approximately $4.54.
How big of a company is Entera Bio?
Entera Bio has a market capitalization of $51.89 million. Entera Bio employs 19 workers across the globe.
What is Entera Bio's official website?
How can I contact Entera Bio?
Entera Bio's mailing address is KIRYAT HADASSAH MINRAV BUILDING FIFTH FLOOR, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected]
MarketBeat Community Rating for Entera Bio (NASDAQ ENTX)
MarketBeat's community ratings are surveys of what our community members think about Entera Bio and other stocks. Vote "Outperform" if you believe ENTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
